Preserving high-value drug product during sterile fill-finish operations is a critical challenge for biopharmaceutical manufacturers, particularly in the early phases of clinical development when batch sizes are limited, and material costs are high. By combining engineering and analytical strategies, manufacturers can minimize product loss and maximize yield. Integrating these approaches and strategies, drug product developers can better protect valuable clinical material, streamline operations, and ensure regulatory compliance—ultimately accelerating timelines and reducing cost in sterile fill-finish development.

Insights you’ll gain:

• How peristaltic pump technology supports product integrity and minimizes hold-up volume during sterile fill-finish operations.
• Best practices for filter selection and sizing to reduce residual loss and align with specific batch size and fill volume needs.
• Strategies for selecting analytical tests that ensure product quality while minimizing material consumption.
• Practical insights on integrating engineering and analytical approaches to maximize yield, preserve high-value drug product, and support regulatory compliance.

Presenters:

	Joe Page, Ph. D. Vice President of Methods Establishment and Manufacturing Eurofins BioPharma Product Testing San Diego
Dr. Joe Page is the Vice President of Methods Establishment and Manufacturing at the Eurofins BioPharma Product Testing San Diego site. He is a pharmaceutical development scientist with more than 30 years of experience leading development, formulation, and manufacturing groups in advancing drug products to commercialization. Joe has worked for both pharmaceutical and contract research organizations and has helped both place products on the market. Joe received his Ph. D. in Chemistry from the University of Washington, Seattle, and did post-doctoral studies in protein chemistry at The Johns Hopkins University.
	Rich Orrell Sterile Fill/Finish Sales Manager Eurofins BioPharma Product Testing
With more than 15 years of pharmaceutical and biotechnology business development experience, Mr. Orrell leads Eurofins’ efforts to grow sterile fill-finish drug product manufacturing in North America. He supports clients developing advanced modalities including AAV, ADCs, mAbs, mRNA, peptides, and lipid nanoparticles, guiding them from preclinical development through clinical supply.